Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment

NCT01580397 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT01580397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01580397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2012
Completion date
July 2, 2013
Enrollment
15 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma